Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Nucleic Acid Therapeutics|April 1, 2016
Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout MiceColby S Shemesh, Rosie Z Yu, Hans J Gaus, et al.
Pharmacology Research & Perspectives|November 26, 2020
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burdenColby S Shemesh, Phyllis Chan, Fatema A Legrand, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancerColby S Shemesh, Pascal Chanu, Kris Jamsen, et al.
Frontiers in Pharmacology|October 13, 2022
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumorsWeize Huang, Felix Stader, Phyllis Chan, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 22, 2019
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin LymphomaDan Lu, Tong Lu, Leonid Gibiansky, et al.
Pharmaceutical Research|December 1, 2020
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin LymphomaDan Lu, Tong Lu, Rong Shi, et al.
Molecular Therapy. Nucleic Acids|December 17, 2017
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOsColby S Shemesh, Rosie Z Yu, Mark S Warren, et al.
Molecular Therapy. Nucleic Acids|May 11, 2016
Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and MonkeysColby S Shemesh, Rosie Z Yu, Hans J Gaus, et al.
Molecular Therapy. Nucleic Acids|May 4, 2016
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in MiceRosie Z Yu, Mark J Graham, Noah Post, et al.
The Lancet. Oncology|November 30, 2019
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 studyBirgit Geoerger, C Michel Zwaan, Lynley V Marshall, et al.
Pageof 3